| Edwards Lifesciences is focused on technologies that treat structural heart disease and ill patients. The products and technologies provided by Co. are categorized into the following main areas: Transcatheter Aortic Valve Replacement, which is engaged in transcatheter heart valve replacement technologies; Transcatheter Mitral and Tricuspid Therapies, which is focused on the development of transcatheter heart valve repair and replacement technologies designed to treat mitral and tricuspid valve diseases; Surgical Structural Heart, which is engaged in cardiac surgical therapies; and Critical Care, which is engaged in hemodynamic monitoring systems.
When researching a stock like Edwards Lifesciences, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from EW Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for EW stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of these ways is called the Relative Strength Index, or RSI. This popular indicator, originally developed in the 1970's by J. Welles Wilder, looks at a 14-day moving average of a stock's gains on its up days, versus its losses on its down days. The resulting EW RSI is a value that measures momentum, oscillating between "oversold" and "overbought" on a scale of zero to 100. A reading below 30 is viewed to be oversold, which a bullish investor could look to as a sign that the selling is in the process of exhausting itself, and look for entry point opportunities. A reading above 70 is viewed to be overbought, which could indicate that a rally in progress is starting to get crowded with buyers. If the rally has been a long one, that could be a sign that a pullback is overdue.